Eli lilly goes all-in on vaccines with $3b+ triple acquisition push into infectious disease prevention

Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

Sanofi India partners with NHM MP to expand NCD, rare disease services

The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units

Healthcare policymakers lay thrust on genetic screening and indigenous therapies for rare diseases

Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules

Merck KGaA launches Phase 3 push for lupus skin disease with enpatoran trials

The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints

AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease

The submission is backed by positive results from the Phase 3 AFFIRM study

New genomics clinic by Fortis Hospitals targets early disease detection

New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care

Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push

The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform